Early results of pharmacogenomic testing pilots are favourable, but insurers are still waiting for final indicators to determine the impact on future drug plan options Several of Canada's insurers are exploring the feasibility of pharmacogenomic (PGx) testing in guiding prescribing decisions and medication use. Here's an update on what they've uncovered so far. Manulife's pilot will wrap up in the fall, but already the insurer is noting changes in 51% of prescriptions after PGx testing. But while a significant proportion of physicians have been interested or very interested in PGx test results, there are still those who are skeptical or have no opinion. It's not surprising then that not all PGx tests are leading to further discussions between patients and prescribers. Alex Carducci, Manulife's product manager, pharmacy benefits, says as the insurer moves forward on this pilot, it will be…
To read this article you must be logged in
We will use your email address to send you our newsletter. All communications will be from TELUS Health.
We will use your email address to send you our newsletter.
All communications will be from TELUS Health.
All fields are required